Organon & Co. (NYSE:OGN) Receives $20.80 Average PT from Brokerages

Shares of Organon & Co. (NYSE:OGN) have earned an average recommendation of “Hold” from the seven research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $20.80.

A number of analysts have weighed in on the company. Barclays lowered their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday. TD Cowen upgraded Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. Finally, Morgan Stanley lowered their price target on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday.

Hedge Funds Weigh In On Organon & Co.

Several large investors have recently made changes to their positions in the company. Talon Private Wealth LLC acquired a new position in shares of Organon & Co. during the fourth quarter valued at $575,000. Schonfeld Strategic Advisors LLC lifted its stake in shares of Organon & Co. by 195.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 63,669 shares of the company’s stock valued at $950,000 after acquiring an additional 42,103 shares during the period. Northern Trust Corp lifted its stake in shares of Organon & Co. by 17.9% during the fourth quarter. Northern Trust Corp now owns 1,914,115 shares of the company’s stock valued at $28,559,000 after acquiring an additional 290,134 shares during the period. Aquatic Capital Management LLC acquired a new position in shares of Organon & Co. during the fourth quarter valued at $327,000. Finally, Oxford Asset Management LLP acquired a new position in shares of Organon & Co. during the fourth quarter valued at $419,000. Institutional investors and hedge funds own 77.43% of the company’s stock.

Organon & Co. Stock Performance

OGN opened at $15.30 on Friday. The stock has a market cap of $3.94 billion, a PE ratio of 3.03, a P/E/G ratio of 0.83 and a beta of 0.76. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. Organon & Co. has a 1 year low of $13.87 and a 1 year high of $23.10. The stock’s 50 day simple moving average is $15.35 and its 200-day simple moving average is $17.42.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $1.57 billion. Organon & Co. had a net margin of 20.30% and a return on equity of 644.70%. Sell-side analysts forecast that Organon & Co. will post 3.82 EPS for the current year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Shareholders of record on Monday, February 24th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a yield of 7.32%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio is currently 22.22%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.